A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy

We investigated the safety and efficacy of nintedanib added to low-dose cytarabine (LDAC) in a phase 1/2 study in patients 60 years or older with newly diagnosed or relapsed/refractory (r/r) AML ineligible for intensive chemotherapy. The results of the dose-finding phase 1 part have been previously...

Descripción completa

Detalles Bibliográficos
Autores principales: Berdel, Andrew F., Koch, Raphael, Gerss, Joachim, Hentrich, Marcus, Peceny, Rudolf, Bartscht, Tobias, Steffen, Björn, Bischoff, Marina, Spiekermann, Karsten, Angenendt, Linus, Mikesch, Jan-Henrik, Kewitz, Tobias, Butterfass-Bahloul, Trude, Serve, Hubert, Lenz, Georg, Berdel, Wolfgang E., Krug, Utz, Schliemann, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807538/
https://www.ncbi.nlm.nih.gov/pubmed/36399194
http://dx.doi.org/10.1007/s00277-022-05025-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807538/
https://www.ncbi.nlm.nih.gov/pubmed/36399194
http://dx.doi.org/10.1007/s00277-022-05025-0

Ejemplares similares